SCHEMBL1993072

SCHEMBL1993072

CC(C)(CN)NC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20531926 0.97 KDM4E (0.44)
SCHEMBL4088521 0.82 ALDH1A1 (0.39)
SCHEMBL12698269 0.81 KDM4E (0.45)
SCHEMBL10861324 0.81 KDM4E (0.37)
Hydrochloric Acid SCHEMBL17142804 0.80 KDM4E (0.38)
SCHEMBL28035771 0.80 KDM4E (0.43)
SCHEMBL11032929 0.79
SCHEMBL7918442 0.79
SCHEMBL12175396 0.78 POLB (0.42)
SCHEMBL9603203 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3686182-A1 CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG Sumitomo Dainippon Pharma Co., Ltd. (JP) 2020-07-29 EP claimed
US-20200207782-A1 CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG SUMITOMO DAINIPPON PHARMA CO., LTD (JP) 2020-07-02 US claimed
WO-2024105007-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF Samsara Therapeutics Inc. (US) 2024-05-23 WO disclosed
EP-3615537-B1 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS NOVARTIS AG (CH) 2024-03-06 EP disclosed
EP-3543242-B1 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND IMPACT THERAPEUTICS SHANGHAI INC (CN) 2024-01-03 EP disclosed
WO-2023180964-A1 PYRAZINE AMIDE DERIVATIVES NOVARTIS AG (CH) 2023-09-28 WO disclosed
US-20230295131-A1 INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE ANGION BIOMEDICA CORP. 2023-09-21 US disclosed
US-20230248835-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER PURDUE RESEARCH FOUNDATION 2023-08-10 US disclosed
WO-2023141852-A1 CDK2 INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF 益方生物科技(上海)股份有限公司 2023-08-03 WO disclosed
US-20230190751-A1 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2023-06-22 US disclosed
WO-2023094305-A1 PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-06-01 WO disclosed
US-20190233425-A1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-08-01 US disclosed
US-20180344738-A1 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors NOVARTIS AG (CH) 2018-12-06 US disclosed
WO-2018198077-A2 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS NOVARTIS AG (CH) 2018-11-01 WO disclosed
US-10100058-B2 Fused heterocyclic compounds as CaM kinase inhibitors GILEAD SCIENCES, INC. (US) 2018-10-16 US disclosed
WO-2018102384-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2018-06-07 WO disclosed
US-20180148457-A1 FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS GILEAD SCIENCES, INC. 2018-05-31 US disclosed
CN-102753548-B Fused heteroaromatic pyrrolidones as SYK inhibitors TAKAEDA CHEMICAL IND LTD 2015-03-11 CN disclosed
US-8440689-B2 Fused heteroaromatic pyrrolidinones TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-14 US disclosed
US-20110152273-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-23 US disclosed